Literature DB >> 22266469

Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes.

Ashley L St John1, Cheryl Y Chan, Herman F Staats, Kam W Leong, Soman N Abraham.   

Abstract

Granules of mast cells (MCs) enhance adaptive immunity when, on activation, they are released as stable particles. Here we show that submicrometre particles modelled after MC granules augment immunity when used as adjuvants in vaccines. The synthetic particles, which consist of a carbohydrate backbone with encapsulated inflammatory mediators such as tumour necrosis factor, replicate attributes of MCs in vivo including the targeting of draining lymph nodes and the timed release of the encapsulated mediators. When used as an adjuvant during vaccination of mice with haemagglutinin from the influenza virus, the particles enhanced adaptive immune responses and increased survival of mice on lethal challenge. Furthermore, differential loading of the particles with the cytokine IL-12 directed the character of the response towards Th1 lymphocytes. The synthetic MC adjuvants replicate and enhance the functions of MCs during vaccination, and can be extended to polarize the resulting immunity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22266469      PMCID: PMC3749235          DOI: 10.1038/nmat3222

Source DB:  PubMed          Journal:  Nat Mater        ISSN: 1476-1122            Impact factor:   43.841


  41 in total

1.  Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2005-12-02       Impact factor: 47.728

Review 2.  Type I interferons in host defense.

Authors:  Daniel B Stetson; Ruslan Medzhitov
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

Review 3.  Particulate systems as adjuvants and carriers for peptide and protein antigens.

Authors:  Ming Tao Liang; Nigel M Davies; Joanne T Blanchfield; Istvan Toth
Journal:  Curr Drug Deliv       Date:  2006-10       Impact factor: 2.565

4.  Avidity of the immunoglobulin G response to a Neisseria meningitidis group C polysaccharide conjugate vaccine as measured by inhibition and chaotropic enzyme-linked immunosorbent assays.

Authors:  Shannon L Harris; How Tsao; Lindsey Ashton; David Goldblatt; Philip Fernsten
Journal:  Clin Vaccine Immunol       Date:  2007-02-07

Review 5.  Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals.

Authors:  P Anderlini; D Przepiorka; R Champlin; M Körbling
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

6.  The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

Authors:  L C Afonso; T M Scharton; L Q Vieira; M Wysocka; G Trinchieri; P Scott
Journal:  Science       Date:  1994-01-14       Impact factor: 47.728

7.  Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA).

Authors:  N McCloskey; M W Turner; T D Goldblatt
Journal:  J Immunol Methods       Date:  1997-06-23       Impact factor: 2.303

Review 8.  Mast cells in the development of adaptive immune responses.

Authors:  Stephen J Galli; Susumu Nakae; Mindy Tsai
Journal:  Nat Immunol       Date:  2005-02       Impact factor: 25.606

Review 9.  Protease-proteoglycan complexes of mouse and human mast cells and importance of their beta-tryptase-heparin complexes in inflammation and innate immunity.

Authors:  Richard L Stevens; Roberto Adachi
Journal:  Immunol Rev       Date:  2007-06       Impact factor: 12.988

10.  Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy.

Authors:  K Roy; H Q Mao; S K Huang; K W Leong
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

View more
  44 in total

1.  Vaccine adjuvants: Tailor-made mast-cell granules.

Authors:  Matthias Gunzer
Journal:  Nat Mater       Date:  2012-02-21       Impact factor: 43.841

Review 2.  Engineering New Approaches to Cancer Vaccines.

Authors:  Naveen K Mehta; Kelly D Moynihan; Darrell J Irvine
Journal:  Cancer Immunol Res       Date:  2015-07-08       Impact factor: 11.151

Review 3.  From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity.

Authors:  Natalie L Trevaskis; Lisa M Kaminskas; Christopher J H Porter
Journal:  Nat Rev Drug Discov       Date:  2015-10-16       Impact factor: 84.694

4.  L-Rhamnose-containing supramolecular nanofibrils as potential immunosuppressive materials.

Authors:  Fan Zhao; Balthasar A Heesters; Isaac Chiu; Yuan Gao; Junfeng Shi; Ning Zhou; Michael C Carroll; Bing Xu
Journal:  Org Biomol Chem       Date:  2014-09-21       Impact factor: 3.876

Review 5.  Mast cell secretory granules: armed for battle.

Authors:  Sara Wernersson; Gunnar Pejler
Journal:  Nat Rev Immunol       Date:  2014-06-06       Impact factor: 53.106

6.  Reprograming immunity to food allergens.

Authors:  Ashley L St John; W X Gladys Ang; Abhay P S Rathore; Soman N Abraham
Journal:  J Allergy Clin Immunol       Date:  2018-02-05       Impact factor: 10.793

7.  Different activation signals induce distinct mast cell degranulation strategies.

Authors:  Nicolas Gaudenzio; Riccardo Sibilano; Thomas Marichal; Philipp Starkl; Laurent L Reber; Nicolas Cenac; Benjamin D McNeil; Xinzhong Dong; Joseph D Hernandez; Ronit Sagi-Eisenberg; Ilan Hammel; Axel Roers; Salvatore Valitutti; Mindy Tsai; Eric Espinosa; Stephen J Galli
Journal:  J Clin Invest       Date:  2016-09-19       Impact factor: 14.808

Review 8.  Targeted immunomodulation using antigen-conjugated nanoparticles.

Authors:  Derrick P McCarthy; Zoe N Hunter; Bryce Chackerian; Lonnie D Shea; Stephen D Miller
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-03-10

9.  Exploiting the pliability and lateral mobility of Pickering emulsion for enhanced vaccination.

Authors:  Yufei Xia; Jie Wu; Wei Wei; Yiqun Du; Tao Wan; Xiaowei Ma; Wenqi An; Aiying Guo; Chunyu Miao; Hua Yue; Shuoguo Li; Xuetao Cao; Zhiguo Su; Guanghui Ma
Journal:  Nat Mater       Date:  2018-01-04       Impact factor: 43.841

Review 10.  Cell and tissue engineering in lymph nodes for cancer immunotherapy.

Authors:  Alexander J Najibi; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2020-08-01       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.